Use of and adherence to antiretroviral therapy in a Large U.S. sample of HIV-infected adults in care, 2007-2008

Open AIDS Journal

Volumn 6, Issue SPEC.ISSUE 1, 2012, Pages 213-223

  Beer, Linda ^a   Heffelfinger, James ^a   Frazier, Emma ^a   Mattson, Christine ^a   Roter, Brad ^b   Barash, Elizabeth ^c,d   Buskin, Susan ^c,d   Rime, Todd ^e   Valverde, Eduardo ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c PUBLIC HEALTH SEATTLE AND KING COUNTY   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e WASHINGTON STATE DEPARTMENT OF HEALTH   (United States)

Author keywords

Antiretroviral therapy; Centers for Disease Control and Prevention (U.S.); HIV; Medication adherence

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; AGE DISTRIBUTION; ANTIVIRAL THERAPY; ARTICLE; BINGE DRINKING; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DISEASE SURVEILLANCE; DRINKING BEHAVIOR; DRUG USE; ETHNIC DIFFERENCE; FEMALE; HEALTH BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; SEX DIFFERENCE; UNITED STATES;

EID: 84871007730     PISSN: None     EISSN: 18746136     Source Type: Journal    
DOI: 10.2174/1874613601206010213     Document Type: Article

References (57)

1. Conway B. The role of adherence to antiretroviral therapy in the management of HIV infection. J Acquir Immune Defic Syndr 2007; 45(Suppl 1): S14-8.
2. Gulick RM. Antiretroviral treatment 2010: progress and controversies. J Acquir Immune Defic Syndr 2010; 55(Suppl 1): S43-8.
3. Bangsberg DR. Less than 95% adherence to nonnucleoside reversetranscriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006; 43(7): 939-41.
4. Martin M, Del Cacho E, Codina C, et al. Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses 2008; 24(10): 1263-8.
5. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333(7557): 15.
6. Granich R, Crowley S, Vitoria M, et al. Highly active antiretroviral treatment for the prevention of HIV transmission. J Int AIDS Soc 2010; 13: 1.
7. Graham SX, Masese L, Gitau R, et al. Antiretroviral adherence and development of drug resistance are the strongest predictors of genital HIV-1 shedding among women initiating treatment. J Infect Dis 2010; 202: 1538-42.
8. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services 2009; pp. 1-161.
9. Pham PA. Antiretroviral adherence and pharmacokinetics: review of their roles in sustained virologic suppression. AIDS Patient Care STDS 2009; 23 (10): 803-7.
10. Reynolds NR, Sun J, Nagaraja HN, Gifford AL, Wu AW, Chesney MA. Optimizing measurement of self-reported adherence with the ACTG Adherence Questionnaire: a cross-protocol analysis. J Acquir Immune Defic Syndr 2007; 46 (4): 402-9.
11. Gill CJ, Sabin LL, Hamer DH, et al. Importance of dose timing to achieving undetectable viral loads. AIDS Behav 2010; 14(4): 785-93.
12. Nilsson Schonnesson L, Williams ML, Ross MW, Bratt G, Keel B. Factors associated with suboptimal antiretroviral therapy adherence to dose, schedule, and dietary instructions. AIDS Behav 2007; 11 (2): 175-83.
13. Schonnesson LN, Williams ML, Ross MW, Diamond PM, Keel B. Three types of adherence to HIV antiretroviral therapy and their association with AIDS diagnosis, medication side-effects, beliefs about antiretroviral therapy, and beliefs about HIV disease. Int J STD AIDS 2007; 18 (6): 369-73.
14. McNaghten AD, Wolfe MI, Onorato I, et al. Improving the representativeness of behavioral and clinical surveillance for persons with HIV in the United States: the rationale for developing a population-based approach. PLoS One 2007; 2 (6): e550.
15. Centers for Disease Control and Prevention. Clinical and Behavioral Characteristics of Adults Receiving Medical Care for HIV Infection: Medical Monitoring Project, 2005 Pilot Data Collection Cycle. HIV Special Surveillance Report 2010; 6.
16. Chesney MA. The elusive gold standard. Future perspectives for HIV adherence assessment and intervention. J Acquir Immune Defic Syndr 2006; 43(Suppl 1): S149-55.
17. Sullivan PS, Campsmith ML, Nakamura GV, Begley EB, Schulden J, Nakashima AK. Patient and regimen characteristics associated with self-reported nonadherence to antiretroviral therapy. PLoS One 2007; 2 (6): e552.
18. Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management. AIDS Behav 2006; 10 (3): 227-45.
19. Cook JA, Cohen MH, Grey D, et al. Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women. Am J Public Health 2002; 92 (1): 82-7.
20. Cook JA, Grey D, Burke-Miller J, et al. Effects of treated and untreated depressive symptoms on highly active antiretroviral therapy use in a US multi-site cohort of HIV-positive women. AIDS Care 2006; 18 (2): 93-100.
21. Giordano TP, White AC Jr, Sajja P, et al. Factors associated with the use of highly active antiretroviral therapy in patients newly entering care in an urban clinic. J Acquir Immune Defic Syndr 2003; 32 (4): 399-405.
22. Kremer H, Ironson G, Schneiderman N, Hautzinger M. To take or not to take: decision-making about antiretroviral treatment in people living with HIV/AIDS. AIDS Patient Care STDS 2006; 20 (5): 335-49.
23. Lemly DC, Shepherd BE, Hulgan T, et al. Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. J Infect Dis 2009; 199 (7): 991-8.
24. Lillie-Blanton M, Stone VE, Snow Jones A, et al. Association of race, substance abuse, and health insurance coverage with use of highly active antiretroviral therapy among HIV-infected women, 2005. Am J Public Health 2010; 100 (8): 1493-9.
25. Palacio H, Kahn JG, Richards TA, Morin SF. Effect of race and/or ethnicity in use of antiretrovirals and prophylaxis for opportunistic infection: a review of the literature. Public Health Rep 2002; 117 (3): 233-51; discussion 1-2.
26. Sherr L, Lampe FC, Clucas C, et al. Self-reported non-adherence to ART and virological outcome in a multiclinic UK study. AIDS Care 2010; 22 (8): 939-45.
27. Barclay TR, Hinkin CH, Castellon SA, et al. Age-associated predictors of medication adherence in HIV-positive adults: health beliefs, self-efficacy, and neurocognitive status. Health Psychol 2007; 26 (1): 40-9.
28. Azar MM, Springer SA, Meyer JP, Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend 2010; 112: 178-93.
29. Hendershot CS, Stoner SA, Pantalone DW, Simoni JM. Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr 2009; 52 (2): 180-202.
30. Braithwaite RS, Conigliaro J, Roberts MS, et al. Estimating the impact of alcohol consumption on survival for HIV+ individuals. AIDS Care 2007; 19 (4): 459-66.
31. Samet J, Walley A. Interventions Targeting HIV-Infected Risky Drinkers: Drops in the Bottle. Alcohol Res Health 2010; 33 (3): 267-79.
32. Parsons JT, Golub SA, Rosof E, Holder C. Motivational interviewing and cognitive-behavioral intervention to improve HIV medication adherence among hazardous drinkers: a randomized controlled trial. J Acquir Immune Defic Syndr 2007; 46 (4): 443-50.
33. Samet JH, Horton NJ, Meli S, et al. A randomized controlled trial to enhance antiretroviral therapy adherence in patients with a history of alcohol problems. Antivir Ther 2005; 10 (1): 83-93.
34. Oh DL, Sarafian F, Silvestre A, et al. Evaluation of adherence and factors affecting adherence to combination antiretroviral therapy among White, Hispanic, and Black men in the MACS Cohort. J Acquir Immune Defic Syndr 2009; 52 (2): 290-3.
35. Silverberg MJ, Leyden W, Quesenberry CP Jr, Horberg MA. Race/ethnicity and risk of AIDS and death among HIV-infected patients with access to care. J Gen Intern Med 2009; 24 (9): 1065-72.
36. Saha S, Jacobs EA, Moore RD, Beach MC. Trust in physicians and racial disparities in HIV care. AIDS Patient Care STDS 2010; 24 (7): 415-20.
37. Bogart LM, Wagner G, Galvan FH, Banks D. Conspiracy beliefs about HIV are related to antiretroviral treatment nonadherence among african american men with HIV. J Acquir Immune Defic Syndr 2010; 53 (5): 648-55.
38. Osborn CY, Paasche-Orlow MK, Davis TC, Wolf MS. Health literacy: an overlooked factor in understanding HIV health disparities. Am J Prev Med 2007; 33 (5): 374-8.
39. Waldrop-Valverde D, Osborn CY, Rodriguez A, Rothman RL, Kumar M, Jones DL. Numeracy skills explain racial differences in HIV medication management. AIDS Behav 2010; 14 (4): 799-806.
40. Geisel-Marbaise S, Stummer H. Diabetes adherence-does gender matter? J Public Health 2010; 18 (3): 219-26.
41. Kuyper LM, Wood E, Montaner JS, Yip B, O'Connell J M, Hogg RS. Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-Infected patients in a population-based cohort. J Acquir Immune Defic Syndr 2004; 37 (4): 1470-6.
42. Turner BJ, Laine C, Cosler L, Hauck WW. Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users. J Gen Intern Med 2003; 18 (4): 248-57.
43. Applebaum AJ, Richardson MA, Brady SM, Brief DJ, Keane TM. Gender and other psychosocial factors as predictors of adherence to highly active antiretroviral therapy (HAART) in adults with comorbid HIV/AIDS, psychiatric and substance-related disorder. AIDS Behav 2009; 13 (1): 60-5.
44. Berg KM, Demas PA, Howard AA, Schoenbaum EE, Gourevitch MN, Arnsten JH. Gender differences in factors associated with adherence to antiretroviral therapy. J Gen Intern Med 2004; 19 (11): 1111-7.
45. Waldrop-Valverde D, Jones DL, Jayaweera D, Gonzalez P, Romero J, Ownby RL. Gender Differences in Medication Management Capacity in HIV infection: the role of health literacy and numeracy. AIDS Behav 2009; 13 (1): 46-52.
46. Ammassari A, Antinori A, Aloisi MS, et al. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics 2004; 45 (5): 394-402.
47. Diiorio C, McCarty F, Depadilla L, et al. Adherence to antiretroviral medication regimens: a test of a psychosocial model. AIDS Behav 2009; 13 (1): 10-22.
48. Shacham E, Nurutdinova D, Onen N, Stamm K, Overton ET. The interplay of sociodemographic factors on virologic suppression among a U.S. outpatient HIV clinic population. AIDS Patient Care STDS 2010; 24 (4): 229-35.
49. Bottonari KA, Safren SA, McQuaid JR, Hsiao CB, Roberts JE. A longitudinal investigation of the impact of life stress on HIV treatment adherence. J Behav Med 2010; 33 (6): 486-95.
50. Dalessandro M, Conti CM, Gambi F, et al. Antidepressant therapy can improve adherence to antiretroviral regimens among HIVinfected and depressed patients. J Clin Psychopharmacol 2007; 27 (1): 58-61.
51. Kleeberger CA, Phair JP, Strathdee SA, Detels R, Kingsley L, Jacobson LP. Determinants of heterogeneous adherence to HIVantiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 2001; 26 (1):82-92.
52. Howard AA, Arnsten JH, Lo Y, et al. A prospective study of adherence and viral load in a large multi-center cohort of HIVinfected women. AIDS 2002; 16 (16): 2175-82.
53. Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence 2010; 4: 115-25.
54. Groves RM. Nonresponse rates and nonresponse bias in household surveys. Public Opin Q 2006; 70 (5): 646-74.
55. Wood E, Kerr T, Hogg RS, Zhang R, Tyndall MW, Montaner JS. Validity of self-reported antiretroviral therapy use among injection drug users. J Acquir Immune Defic Syndr 2006; 41 (4): 530-31.
56. Kalichman SC, Rompa D, Cage M. Reliability and validity of selfreported CD4 lymphocyte count and viral load test results in people living with HIV/AIDS. Int J STD AIDS 2000; 11 (9): 579-85.
57. Kinsler J, Cunningham W, Mohanty S, Wong M. Are medical records a more reliable and valid source of CD4 count, viral load, and outpatient visit data than self-reports? A comparison with electronic medical records as the gold standard. Health Serv Outcomes Res Methodol 2008; 8 (4): 187-200.